RAD-140 and Raloxifene Interaction

Avoid
Mechanism-based 53% confidence

RAD-140 and Raloxifene have a potentially harmful interaction with 53% confidence. Both RAD-140 and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads, so monitoring these systems is recommended.

Compound Profiles

RAD-140

Selective Androgen Receptor Modulator | Investigational SARM

RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands.

Half-life: ~60 hours Typical dose: 10-20 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskcrosses bbb
View full profile

Raloxifene

Selective Estrogen Receptor Modulator | Gynecomastia & Bone Health

Raloxifene binds to both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta), producing tissue-dependent agonist or antagonist effects determined by the local complement of coactivator and corepressor proteins. In breast tissue, raloxifene functions as a potent estrogen antagonist, blocking estradiol-mediated proliferative signaling with high selectivity.

Half-life: ~28 hours Typical dose: 60mg oral daily pct
estrogen receptor hepatotoxicpct agentteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Pituitary
low

Shared Safety Flags

2x 2 hepatotoxic compounds (RAD-140, Raloxifene). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.

Frequently Asked Questions

Can I take RAD-140 with Raloxifene?

Combining RAD-140 with Raloxifene is not recommended. Both RAD-140 and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is RAD-140 and Raloxifene safe together?

This combination carries significant risk. Both RAD-140 and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between RAD-140 and Raloxifene?

Both RAD-140 and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 53% confidence and is inferred from pharmacological mechanism analysis.

How should I time RAD-140 and Raloxifene?

RAD-140 has a half-life of ~60 hours and Raloxifene has a half-life of ~28 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: RAD-140 vs Raloxifene

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.